Focused On-demand Library for H(+)/Cl(-) exchange transporter 6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Chloride channel protein 6; Chloride transport protein 6

Alternative UPACC:

P51797; A8K1T4; B4DGT7; F8W9R3; O60818; O60819; O60820; O60821; P78520; P78521; Q17R81; Q5SNW2; Q5SNW3; Q5SNX1; Q5SNX2; Q5SNX3; Q99427; Q99428; Q99429


H(+)/Cl(-) exchange transporter 6, also known as Chloride channel protein 6 or Chloride transport protein 6, plays a crucial role in cellular processes by mediating the exchange of chloride ions against protons. This action contributes significantly to the acidification of the late endosome lumen, a process vital for cellular homeostasis. The protein is a member of the CLC channel family, which includes both chloride channels and proton-coupled anion transporters.

Therapeutic significance:

The protein is implicated in a severe neurodegenerative disorder, characterized by developmental delay, respiratory insufficiency, and brain abnormalities. Understanding the role of H(+)/Cl(-) exchange transporter 6 could open doors to potential therapeutic strategies for this debilitating condition.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.